A Study of Atezolizumab as First-line Monotherapy for Advanced or Metastatic Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2019-05-14
Target enrollment:
Participant gender:
Summary
This was a Phase II, open-label, prospective, multicenter study designed to evaluate the
efficacy and safety of single-agent atezolizumab as a first-line therapy in participants with
locally advanced or metastatic non-small cell lung cancer (NSCLC). In addition, the primary
biomarker objective was to measure blood tumor mutational burden (bTMB) and evaluate whether
it can predict for improved clinical outcome with atezolizumab.